Received May 22, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
suspected vaccination failure; Shingles flare ups; 42-year patient; This serious case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a 42-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced vaccination failure (Verbatim: suspected vaccination failure) (serious criteria GSK medically significant), shingles (Verbatim: Shingles flare ups) and inappropriate age at vaccine administration (Verbatim: 42-year patient). The outcome of the vaccination failure was not reported and the outcome of the shingles was not resolved and the outcome of the inappropriate age at vaccine administration was not applicable. It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingrix. The company considered the vaccination failure to be unrelated to Shingrix. It was unknown if the company considered the shingles to be related to Shingrix. Additional Information: GSK Receipt Date:17-MAY-2026 This case was reported by a patient via interactive digital media. The patient was 42 years and was getting flare ups for about 5 years now. The reporter stated that thanks to the vaccines. The batch number was not provided and unable to contact the reporter. This case was considered as suspected vaccination failure as details regarding completion of primary vaccination schedule, time to onset for shingles and laboratory confirmation regarding shingles were unknown at the time of reporting.; Sender's Comments: A case of Vaccination failure, unknown time after receiving Shingrix in a 42-year-old female patient. Case lacks further information on time to onset, medical history, concurrent conditions, completion of primary vaccination schedule and laboratory confirmation. Based on the available information a possible causality that the event was caused by the GSK product cannot be ascertained. Consent for further follow-up has not been received.